The Desmond Tutu HIV Centre is currently conducting the following HIV trials:
A400-1026: A multi-centre, Randomised, Double -blind, Comparative Trial of a novel CCR5 antagonist, UK-427,857 in combination with Zidovudine/Lamivudine versus Efavirenz in combination with Zidovudine/Lamivudine for the treatment of antiretroviral naïve HIV-1 infected subjects.
APV30005: An open label phase 3 study to assess the safety profile of GW433908 containing regimens in HIV-1 infected subjects
AVX-301: A phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V/I mutation in reverse transcriptase
BI1100.1486: A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID nevirapine immediate release in combination with Truvada® in antiretroviral therapy naïve HIV-1 infected patients (VERVE)
TMC114-C214: A Randomised, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/Ritonavir versus Lopinavir/Ritonavir in treatment experienced HIV-1 infected subjects.
TMC278-TiDP6-C209: A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects
TMC114-C211: ARTEMIS; A randomised, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/Ritonavir versus Lopinavir/Ritonavir in treatment naïve HIV-1 infected subjects.
TMC278-C204: A phase 2B randomised, partially blinded, dose-finding trial of TMC278-C204 in antiretroviral naïve HIV-1 Infected subjects.
TMC114-TiDP31 C229: A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100mg) q.d. versus DRV/rvt (600/100mg) b.i.d in early treatment-experienced HIV-1 infected subjects
PO3672: Vicroviroc (SCH417690) in combination with ART regimen in experienced subjects.(VICTOR-E1)
PO4889: Vicriviroc in combination treatment with an optimised ART regimen in HIV-infected treatment experienced subjects(VICTOR-E4)
PO4875: Efficacy and Safety of Vicriviroc in HIV-infected treatment naïve subjects.
PrEP: Chemoprophylaxis for HIV prevention in Men
VIR201-04-06: A Phase I/IIa, double-blind, randomised, placebo-controlled, parallel group study to determine the safety, tolerability and immunogenicity of an HIV-1 immunotherapeutic vaccine expressing Clade B antigens Gag and Pol (VIR201) in HIV-1-positive participants
START: Strategic Timing of AntiRetroviral Treatment
IAVI LTFU: Long Term Follow-up of study participants from IAVI sponsored clinical trials with HIV candidate vaccines
